CD150 (IPO3/SLAM) belongs to the SLAM family of receptors and serves as a major entry receptor for measles virus. CD150 is expressed on normal and malignant cells of the immune system. However, little is known about its expression outside the hematopoietic system, especially tumors of the central nervous system (CNS). Although CD150 was not found in different regions of normal brain tissues, our immunohistochemical study revealed its expression in 77.6% of human CNS tumors, including glioblastoma, anaplastic astrocytoma, diffuse astrocytoma, ependymoma, and others. CD150 was detected in the cytoplasm, but not on the cell surface of glioma cell lines, and it was colocalized with the endoplasmic reticulum and Golgi complex markers. In addition to the full length mRNA of the mCD150 splice isoform, in glioma cells we found a highly expressed novel CD150 transcript (nCD150), containing an 83 bp insert. The insert is derived from a previously unrecognized exon designated Cyt-new, which is located 510 bp downstream of the transmembrane region exon, and is a specific feature of primate SLAMF1. Both mCD150 and nCD150 cDNA variants did not contain any mutations and had the leader sequence. The nCD150 transcript was also detected in normal and malignant B lymphocytes, primary T cells, dendritic cells and macrophages; however, in glioma cells nCD150 was found to be the predominant CD150 isoform. Similarly to mCD150, cell surface expression of nCD150 allows wild type measles virus entry to the cell. Our data indicate that CD150 expression in CNS tumors can be considered a new diagnostic marker and potential target for novel therapeutic approaches.

Eukaryotic elongation factor 1 (eEF1) mediates the binding of aminoacyl-tRNA to the ribosome in GTP-dependent manner. eEF1 consists of four subunits: eEF1A, eEF1Ba, eEF1Bb and eEF1Bg. eEF1A has two different isoforms: eEF1A1 is present throughout development and is ubiquitously expressed with the exception of adult muscle, while eEF1A2 is developmentally regulated and expressed only in muscle cells and neurons. Expression of eEF1A1, eEF1A2, eEF1Ba, eEF1Bb and eEF1Bg genes was analyzed by Northern blot hybridization of a panel of brain tumor and normal brain tissue RNAs. Totally 23 glioblastoma and 10 normal brain samples were investigated. In gliomas, no meaningful difference in the mRNA content for the eEF1A1, eEF1Ba and eEF1Bg subunits as compared to normal brain tissues was found. However, we have observed approximately 2-fold decrease in the eEF1Bb mRNA expression in human gliomas as compared to normal human brain by Northern blot analysis. Besides, we have shown reduced level of the eEF1A2 mRNA expression in glioblastoma as compared to normal human glia.

The aim of the work was to study the impact of fetal rat brain cell supernatant (FRBCS) on the expression of transforming growth factor β1 (TGF-β1) and p53 in C6 cells of rat glioma in vitro. Materials and Methods: FRBCS was obtained from suspensions of fetal rat brain cells on the 14th (E14) day of gestation. C6 glioma cells were cultured for 48 h in the presence of FRBCS or FRBCS + anti-TGF-β1 monoclonal antibody. Immunocytochemical staining for TGF-β1 and p53 was performed. Results: The proportion of TGF-β1-immunopositive tumor cells in C6 glioma cultures was statistically significantly higher than in the control cell cultures of normal fetal rat brain. FRBCS reduced the proportion of TGF-β1-immunopositive tumor cells and increased the proportion of p53-immunopositive cells in C6 glioma cultures. In cells cultured with FRBCS + anti-TGF-β1 monoclonal antibody, the above effects of FRBCS were abrogated. Conclusion: The obtained results suggest that TGF-β1 seems to be responsible for decrease in TGF-β1 expression and increase in p53 expression in C6 glioma cells treated with FRBCS.

No abstract

Aim. To investigate protein level of all subunits of the eukaryotic elongation translation factor eEF1H (eEF1A, eEF1Bα, eEF1Bβand eEF1Bγ) in glial tumors of human brain in comparison with normal brain. Methods. The eEF1H components content has been investigated in human glioblastoma clinical samples by Western blot analysis. Results. To determine the eEF1Bα, eEF1Bβ and eEF1Bγ content, the polyclonal antibodies against all eEF1H subunits were obtained. The tendency of the eEF1Bγ protein level to increase in glioblastomas was observed. There were no significant differences in the eEF1A, eEF1Bα and eEF1Bβ protein contents. Conclusions. In the previous report we analysed the expression of all eEF1H subunits in human glial brain tumor on the mRNA level. This study showed that eEF1Bγ was overexpressed while no significant changes in other eEF1H subunits were observed. It suggests a possible function of eEFBg which is cancer-related and is not connected with the functioning of eEF1H complex in translation